Programs & products

IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL). Phase I trial is expected to start in 2015 IPH4102 shows potent...

This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma This new Phase I initiated by Bristol...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...

IPH4102 is a first-in-class anti-KIR3DL2 antibody Phase I is expected to start in 2015 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today holds an R&D...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced the...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data...

Novo Nordisk to reinforce its equity stake in Innate Pharma Marseille, France and Bagsværd, Denmark, 5 February 2014 Anti-NKG2A is a first-in-class therapeutic mAb that is Phase II ready NKG2A is a NK...

MICA validated as a novel target for antibody drug development in solid tumors IPH43 program now aims at selection and optimization of the best development candidate Innate Pharma SA (the “Company” -...

Evidence for lirilumab single-agent activity in lymphoma Demonstration of enhanced efficacy of anti-CD20 antibodies when combined with lirilumab To be presented at ASH meeting, December 9, abstract...